phosphoric acid bis-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl] ester | 615288-02-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: phosphoric acid bis-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl] ester
• 英文别名: Phosphoric acid bis-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-ester；bis[5,5-dimethyl-6-(oxan-2-yloxy)hexyl] hydrogen phosphate
• CAS: 615288-02-3
• 化学式: C₂₆H₅₁O₈P
• 分子量: 522.66
• InChiKey: UUTWLQOWKMLNFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  35
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  92.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  phosphoric acid bis-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl] ester 在 二氯甲烷 、 碳酸氢钠 、 magnesium sulfate 作用下， 以 甲醇 、 盐酸 、 水 为溶剂， 反应 2.0h， 以to give phosphoric acid bis-(5,5-dimethyl-6-hydroxyhexyl)-ester (1.73 g, 4.88 mmol, 9% over both steps) as a viscous oil的产率得到phosphoric acid bis-[5,5-dimethyl-6-hydroxyhexyl]ester
  参考文献：
  名称：

  Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses

  摘要：

  本发明涉及新型酰基辅酶A类似物、包含酮类化合物的组合物以及用于治疗和预防心血管疾病、血脂异常、蛋白质异常和葡萄糖代谢紊乱的方法，包括给予含有酮类化合物的组合物。本发明的酰基辅酶A类似物、组合物和方法还可用于治疗和预防阿尔茨海默病、综合征X、过氧化物酶体增殖物激活受体相关疾病、败血症、血栓性疾病、肥胖症、胰腺炎、高血压、肾脏疾病、癌症、炎症、细菌感染和阳痿。在某些实施方式中，本发明的酰基辅酶A类似物、组合物和方法可与其他治疗药物，如降胆固醇和降血糖药物一起用于联合治疗。

  公开号：

  US20030236212A1
• 作为产物：
  描述：

  6-溴-2,2-二甲基己酸乙酯 在 锂硼氢 、 potassium carbonate 、 对甲苯磺酸 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 20.5h， 生成 phosphoric acid bis-[5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl] ester
  参考文献：
  名称：

  Influence of Various Central Moieties on the Hypolipidemic Properties of Long Hydrocarbon Chain Diols and Diacids

  摘要：

  A series of long (11-15) hydrocarbon chain diols and diacids with various central functional groups and terminal gem-dimethyl or -methyl/aryl substituents was synthesized and evaluated in both in vivo and in vitro assays for its potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes, as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats, Crl:(ZUC)-faBR. The most active compounds were hydroxyl-substituted symmetrical diacids and diols with a 13-atom chain and terminal gem-dimethyl substituents. Furthermore, biological activity was enhanced by central substitution with O, C=O, S, S=O compared to the methylene analogues and was diminished for compounds with central functional groups such as carbamate, ester, urea, acetylmethylene, and hydroxymethylene.

  DOI：

  10.1021/jm050650j

文献信息

• Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses
  申请人：——

  公开号：US20030236212A1

  公开（公告）日：2003-12-25

  The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

  该发明涉及新型酰辅酶A类似物，包含酮化合物的组合物，以及用于治疗和预防心血管疾病、血脂异常、蛋白异常和葡萄糖代谢紊乱的方法，包括给予含有酮化合物的组合物。该发明的酰辅酶A类似物、组合物和方法也适用于治疗和预防阿尔茨海默病、X综合征、过氧化物酶体增殖激活受体相关疾病、败血症、血栓性疾病、肥胖、胰腺炎、高血压、肾脏疾病、癌症、炎症、细菌感染和阳痿。在某些实施例中，该发明的酰辅酶A类似物、组合物和方法可与其他治疗药物（如降胆固醇和降血糖药物）联合治疗。
• Influence of Various Central Moieties on the Hypolipidemic Properties of Long Hydrocarbon Chain Diols and Diacids
  作者：Daniela C. Oniciu、Jean-Louis H. Dasseux、Jing Yang、Ralf Mueller、Emil Pop、Anna Denysenko、Caiming Duan、Tian-Bao Huang、Lianhao Zhang、Brian R. Krause、Sandra L. Drake、Narendra Lalwani、Clay T. Cramer、Brian Goetz、Michael E. Pape、Andrew McKee、Gregory J. Fici、Janell M. Lutostanski、Stephen C. Brown、Charles L. Bisgaier

  DOI：10.1021/jm050650j

  日期：2006.1.1

  A series of long (11-15) hydrocarbon chain diols and diacids with various central functional groups and terminal gem-dimethyl or -methyl/aryl substituents was synthesized and evaluated in both in vivo and in vitro assays for its potential to favorably alter lipid disorders including metabolic syndrome. Compounds were assessed for their effects on the de novo incorporation of radiolabeled acetate into lipids in primary cultures of rat hepatocytes, as well as for their effects on lipid and glycemic variables in obese female Zucker fatty rats, Crl:(ZUC)-faBR. The most active compounds were hydroxyl-substituted symmetrical diacids and diols with a 13-atom chain and terminal gem-dimethyl substituents. Furthermore, biological activity was enhanced by central substitution with O, C=O, S, S=O compared to the methylene analogues and was diminished for compounds with central functional groups such as carbamate, ester, urea, acetylmethylene, and hydroxymethylene.